“Gedatolisib plus Faslodex, with or without Ibrance, represents a potential new standard of care for patients with hormone ...

Researchers sought to determine whether zanubrutinib plus obinutuzumab would be effective in treating patients with R/R FL. Researchers determined zanubrutinib plus obinutuzumab demonstrated sustained ...

In 2025, the medtech industry saw another year full of all kinds of deals in the mergers and acquisitions (M&A) arena.

In 2025, Asbury Park Press journalists produced a steady stream of the kind of work that tells readers we do this for you, to ...